Company / Cash & Equivalents
Exelixis Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$482.5M
FY2025
5-year range
$217.4M / $647.2M
FY2021-FY2025
Trend
+122.0%
vs FY2024
Sector context
#44 of 207
Health Care
What the data says
Exelixis's cash & equivalents of $482M is higher than 79% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $482M.
Based on SEC 10-K filings.
$482M in FY2025 with a 5-year CAGR of +8.6%. Top quartile in the Health Care sector.
Improved from $263M to $482M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -1.3%
- 5-Year CAGR
- +8.6%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 207This company $482.5M Sector average $669.5M
▼
-27.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 122.0% year-over-year.
- Ranks #44 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $482.5M | +122.0% |
| FY2024 | $217.4M | -17.3% |
| FY2023 | $263.0M | -47.5% |
| FY2022 | $501.2M | -22.6% |
| FY2021 | $647.2M | +102.7% |
| FY2020 | $319.2M | +19.8% |
| FY2019 | $266.5M | +75.7% |
| FY2018 | $151.7M | -17.2% |
| FY2017 | $183.2M | +20.8% |
| FY2016 | $151.7M | +88.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026